Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 14 , ISSUE 1 ( January-June, 2024 ) > List of Articles

Original Article

Is Aspartate Aminotransferase to Platelet Ratio Index a Better Noninvasive Score for Predicting Advanced Fibrosis in Nonalcoholic Fatty Liver Disease Patients?

Priyansh D Bhayani, Sarojini A Parameswaran, Kallippatti R Palaniswamy, Paramasivan Piramanayagam, Natarajan Murugan

Keywords : Aspartate aminotransferase to platelet ratio index score, FibroScan, Fibrosis-4 score, Nonalcoholic fatty liver disease, Nonalcoholic fatty liver disease fibrosis score

Citation Information : Bhayani PD, Parameswaran SA, Palaniswamy KR, Piramanayagam P, Murugan N. Is Aspartate Aminotransferase to Platelet Ratio Index a Better Noninvasive Score for Predicting Advanced Fibrosis in Nonalcoholic Fatty Liver Disease Patients?. Euroasian J Hepatogastroenterol 2024; 14 (1):35-39.

DOI: 10.5005/jp-journals-10018-1425

License: CC BY-NC 4.0

Published Online: 12-06-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background: In the 21st century, nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disorder. The prevalence of NAFLD within the general population in India ranges from 9 to 53%. The gold standard for assessing the severity of liver fibrosis is liver biopsy. However, due to various difficulties involved with liver biopsy, it is imperative to identify different non-invasive tools that can replace liver biopsy. Methodology: A prospective observational study of 130 patients meeting the inclusion criteria for NAFLD was done for a period of 18 months. We aimed to compare the performance characteristics of different noninvasive scores [fibrosis-4 (FIB-4) score, nonalcoholic fatty liver disease fibrosis score (NFS), and aspartate aminotransferase to platelet ratio index (APRI)] in predicting advanced fibrosis as assessed by FibroScan. Results: In the study, 76.9% of patients were male. Advanced fibrosis was seen in 12.3% of the patients. Majority of the patients with advanced fibrosis had metabolic syndrome. Based on the area under the receiver operating characteristic curve (AUROC), the new cut-off for ruling out advanced fibrosis for FIB-4, NFS, and APRI were 1.18, −0.9, and 0.65, respectively, and APRI had the best AUROC (0.768). Conclusion: Abnormal glycemic status and metabolic syndrome were risk factors for advanced fibrosis. The newly derived cut-offs for the FIB-4 score, NFS score, and APRI score had a better Negative predictive value compared to the original cut-offs.


PDF Share
  1. Mansour AMF, Bayoumy EM, ElGhandour AM, et al. Assessment of hepatic fibrosis and steatosis by vibration-controlled transient elastography and controlled attenuation parameter versus non-invasive assessment scores in patients with non-alcoholic fatty liver disease. Egypt Liver J 2020;10(1):33. DOI: 10.1186/s43066-020-00044-w.
  2. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148(3):547–555. DOI: 10.1053/j.gastro.2014.11.039.
  3. Angulo P, Kleiner DE, Dam–Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149(2):389e.10–397.e10. DOI: 10.1053/j.gastro.2015.04.043.
  4. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15(1):11–20. DOI: 10.1038/nrgastro.2017.109.
  5. Duseja A, Singh SP, Saraswat VA, et al. Nonalcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol 2015;5(1):51–68. DOI: 10.1016/j.jceh.2015.02.006.
  6. Duseja A, Najmy S, Sachdev S, et al. High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India. JGH Open Open Access J Gastroenterol Hepatol 2019;3(2):133–139. DOI: 10.1002/jgh3.12117.
  7. Vuppalanchi R, Siddiqui MS, Van Natta ML, et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 2018;67(1):134–144. DOI: 10.1002/hep.29489.
  8. Petta S, Wong VWS, Cammà C, et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology 2017;65(4):1145–1155. DOI: 10.1002/hep.28843.
  9. Fallatah HI. Noninvasive biomarkers of liver fibrosis: An overview. Adv Hepatol 2014;2014:e357287. DOI: 10.1155/2014/357287.
  10. Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14(6):889–919. DOI: 10.1007/s12072-020-10094-2.
  11. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156(6):1717–1730. DOI: 10.1053/j.gastro.2019.01.042.
  12. Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol WJG 2014;20(45): 16820–16830. DOI: 10.3748/wjg.v20.i45.16820.
  13. Fallatah HI, Akbar HO, Fallatah AM. FibroScan compared to FIB-4, APRI, and AST/ALT ratio for assessment of liver fibrosis in Saudi patients with nonalcoholic fatty liver disease. Hepat Mon 2016;16(7):e38346. DOI: 10.5812/hepatmon.38346.
  14. Amernia B, Moosavy SH, Banookh F, et al. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterol 2021;21(1):453. DOI: 10.1186/s12876-021-02038-3.
  15. Mahady SE, Macaskill P, Craig JC, et al. Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis. Clin Gastroenterol Hepatol 2017;15(9):1453.e1–1460.e1. DOI: 10.1016/j.cgh.2017.02.031.
  16. McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with nonalcoholic fatty liver disease. Gut 2010;59(9): 1265–1269. DOI: 10.1136/gut.2010.216077.
  17. Shamseya AM, Afify MT, Fayad HAS, et al. Real-time elastography FibroScan compared to simple non-invasive screening tools in the assessment of liver fibrosis in non-alcoholic fatty liver patients. Egypt Liver J 2022;12(1):35. DOI: 10.1186/s43066-022-00197-w.
  18. Mohamed RA, Nabih MI, ElShobaky MB, et al. The value of noninvasive scoring systems for the diagnosis of advanced fibrosis in Egyptian patients with nonalcoholic fatty liver disease. Egypt J Intern Med 2014;26(4):162–169. DOI: 10.4103/1110-7782.148151.
  19. Kolhe KM, Amarapurkar A, Parikh P, et al. Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population. BMJ Open Gastroenterol 2019;6(1):e000288. DOI: 10.1136/bmjgast-2019-000288.
  20. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7(10):1104–1112. DOI: 10.1016/j.cgh.2009.05.033.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.